Brought to you by
ECR 2018 / C-3001
Transarterial Chemo-embolisation with degradable starch microspheres(DSM-TACE) in intermediate/advanced HCC patients dismissing or inelegible for Sorafenib
Congress: ECR 2018
Poster No.: C-3001
Type: Scientific Exhibit
Keywords: Oncology, Interventional non-vascular, Liver, Catheter arteriography, Percutaneous, CT, Chemoembolisation, Chemotherapy, Treatment effects, Cancer
Authors: F. Carchesio, R. Iezzi, A. Posa, M. Pompili, A. Gasbarrini, R. Manfredi; Rome/IT
DOI:10.1594/ecr2018/C-3001

Results

A total of 86 treatments were performed. Technical success, defined as the ability to deliver the total planned dose or to obtain stop flow, was achieved in all patients. No intra- or peri-procedural complications occurred and in particular no signs of liver failure or systemic toxicity were detected. At 1-month follow-up, an objective response rate (ORR) of 45.9% and overall disease control (ODC) of 79.2% were observed. In nine patients with ODC and residual viable tumor higher than 50%, a repeated DSM-TACE treatment was performed. During the mean follow-up of 18.2 months an ODC of 45.8% was registered. PFS, calculated using the Kaplan-Meier method, was 5.8 months with a median OS of 10.8 months (Fig. 1; Fig.2).

When considering the subgroup evaluation (Fig.3), significant longer overall survival was obtained for BCLC-B intermediate Child-Pugh A patients compared with BCLC-C advanced  Child-Pugh B patients. The outcome justifies  the prognostic pivotal role of liver functional reserve in intermediate/advanced HCC patients with liver cirrhosis which has been previously described by other groups.

POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
SHARE THIS POSTER
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more